GRASP-HF v1.0

  • Research type

    Research Study

  • Full title

    Snapshot study on patient with Heart failure

  • IRAS ID

    344602

  • Contact name

    Emilie Soriano

  • Contact email

    registries@escardio.org

  • Clinicaltrials.gov Identifier

    2024-A01000-47, N° ID RCB (French authority ANSM)

  • Duration of Study in the UK

    1 years, 3 months, 31 days

  • Research summary

    Heart failure (HF) is a multi-event disease and despite of the development of beneficial treatments, clinical outcomes remain poor and 5-year survival equals or it is even lower than many forms of cancers.
    The European Society of Cardiology (ESC) has recognized HF as a disease with a particular need for continuous epidemiological research to describe more accurately the demographic, clinical, and therapeutic characteristics of patients with HF, in both acute and chronic settings.
    GRASP-HF study is a prospective, international, multicentric, longitudinal study with short period of enrolment (2 months) and a 6-month follow-up.
    The general objectives of the study are :
    1) to provide a better understanding of medical practice based on real-world data, collected both across Europe and the rest of the world, using robust methodology and representativeness within each country
    2) To assess contemporary patterns of HF management in practice and to assess adherence to the 2021 ESC HF Guidelines, and how these patterns relate to outcomes.
    The study will include all adult outpatients with HF seen at the clinics, and those admitted for acute, pre-existing or new onset HF to participating centres during the enrolment period.
    The protocol does not involve any specific interventions and aims to capture the usual healthcare of patients suffering from HF (data collection from patient's medical records). The protocol includes a baseline visit and a follow-up at 6 months during a visit, a call or from other medical reports. Data collection includes (non-exhaustive): demographic characteristics, clinical history, HF-related risk-factors, diagnostic, treatments, frailty, quality of life questionnaire (EuroQOL EQ-5D if done as per routine care), survival status.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    24/WM/0167

  • Date of REC Opinion

    16 Sep 2024

  • REC opinion

    Further Information Favourable Opinion